KR101558476B1

KR101558476B1 - Novel Use of Filvertone

Info

Publication number: KR101558476B1
Application number: KR1020150077575A
Authority: KR
Inventors: 박태선
Original assignee: 연세대학교 산학협력단
Priority date: 2015-06-01
Filing date: 2015-06-01
Publication date: 2015-10-12
Also published as: WO2016195355A1

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases comprising filbertone, and to a functional food composition for alleviating or mitigating metabolic diseases by using the same. The filbertone of the present invention can be usefully used as a pharmaceutical or functional food composition, which represents activation of preventing or treating metabolic diseases, selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver, insulin resistance syndrome, by reducing a weight and visceral fat, reducing blood lipid concentration, improving a blood liver function index, reducing blood sugar, and inhibiting metabolic inflammatory response.

Description

Novel Use of Filvertone < RTI ID = 0.0 >

The present invention relates to a pharmaceutical composition for the prevention or treatment of metabolic diseases, comprising a flavone as an active ingredient, and a functional food composition for preventing or improving metabolic diseases.

Due to the changes in the living environment, the incidence of metabolic syndrome accompanied by diabetes, hypertension, lipid metabolism abnormality, and insulin resistance is increasing rapidly as modern visceral obesity increases. These diseases increase the risk of mutual occurrence and are a common disease associated with multiple metabolic changes such as aging, stress, and impaired immune function. Obesity causes not only appearance problems but also chronic diseases such as fatty liver, hypertension, diabetes, cardiovascular diseases and the like.

More than 300 million people in the western region, including the United States, Europe and Japan in the main markets of the United States, Europe and Japan, are overweight and obese (BMI> 30). . Among the OECD countries, the United States has the highest percentage of obesity, followed by Mexico (24%), Britain (23%), Greece (22%), Australia (22% (13%), Germany (13%), Finland (13%), Finland (13%), Turkey (13%), New Zealand (21%), Hungary 12%), and Belgium (12%). The proportion of obese people in the total population is high in China, with 70 million people obese, and the market for weight control is rapidly expanding, Of the total number of children in the world is currently one of the five obesity pediatric obesity, and the number is rapidly increasing, so that childhood obesity is becoming a serious social problem.Patiently obesity, blood cholesterol and triglyceride levels Of diabetes, high blood pressure, stroke, and so on, 80% of childhood obesity As more and more fat is stimulated, sex hormone secretion stimulates puberty faster than age and can lead to growth disorders, blood circulation and nutrition It also affected supply, causing growth inhibition.

Non-alcoholic fatty liver disease (NAFLD) refers to a disease in which hepatic triglyceride accumulates in the liver regardless of alcohol, including steatosis and non-alcoholic steatohepatitis, NASH). Simple fatty liver is thought to be a benign benign disease with good clinical prognosis. However, NASH with inflammation or fibrosis with fatty liver is a progressive liver disease and is recognized as a disease causing cirrhosis or liver cancer.

Obesity and insulin resistance are major risk factors for nonalcoholic fatty liver disease. Risk factors for progression of liver fibrosis include obesity (BMI> 30), serum liver function index (AST / ALT> 1), and diabetes mellitus. There is a need for prevention and treatment. 69-100% of nonalcoholic fatty liver patients are obese, and 20-40% of obese patients are accompanied by nonalcoholic fatty liver. Especially, the prevalence of liver disease in male obese patients is higher than that of female obese patients. In Western countries, not only obese patients but also 3 to 30% of normal weight adults are reported to have nonalcoholic fatty liver lesions. The prevalence of nonalcoholic fatty liver in Japan is estimated to be about 20%, of which 1% is estimated to be NASH. Nonalcoholic fatty liver is a problem not only in adults but also in obese children. 10-77% of obese children (in Europe, USA and Asia) have nonalcoholic fatty liver lesions because obesity is the most important risk factor for nonalcoholic liver disease.

Among the obesity drugs marketed at home and abroad are 'Xenical' (Korean Roche), which is approved by the US FDA, 'Reductil' (sickle cellulase) based on sibutramine, and 'Exo' Rizhe '(Gugu Pharmaceutical). In the case of xenical inhibiting the lipase action, gastrointestinal side effects such as lowering of fat, gas production, and fat-soluble vitamin absorption are increased, and in the case of reductil, the concentration of serotonin and noradrenaline in the sympathetic nervous system is increased to cause headache, dry mouth, loss of appetite, And the like. In addition, many anti-obesity products have been banned due to serious side effects. For example, aminophylline has been reported to have a wide range of adverse effects on the mental nervous system, circulatory system, and digestive system in spite of the excellent body fat decomposition effect, and penfluramine, dexfenfluramine, topirameye, ephedrine, And sales were prohibited. As such, conventional synthetic drugs show limitations due to side effects, and there is a growing demand for the development of a novel composition for the treatment of obesity that is safe and can be taken for a long time and is suitable for the treatment of chronic diseases.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

Korea Patent No. 1078376 Korean Patent No. 1186500

The present inventors have made extensive efforts to develop compounds having an activity of preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. As a result, the present inventors have completed the present invention by confirming that filbertone has a preventive, ameliorating and therapeutic effect on the metabolic diseases by reducing the body fat and blood sugar and greatly improving the index of various metabolic diseases .

Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, which comprises peptone as an active ingredient.

It is still another object of the present invention to provide a functional food composition for preventing or ameliorating metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, which comprises peptone as an active ingredient.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

In accordance with one aspect of the present invention, the present invention provides a method of treating metabolic disorders selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome comprising filbertone as an active ingredient A pharmaceutical composition for the prevention or treatment of metabolic disease is provided:

The present inventors have made extensive efforts to develop compounds having an activity of preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. As a result, it has been confirmed that filbertone reduces the fat and blood sugar in the body and significantly improves the index of various metabolic diseases, and thus has a preventive, ameliorative and therapeutic effect on the metabolic diseases.

As used herein, the term " fillbutone " is a natural compound represented by the following formula (1). The formula is C ₈ H ₁₄ O and its molecular weight is 126.2 g / mol. Flavone is known as a safe and safe food. Flavor and fragrance agents are added to Flavor and Extract Manufacturers Association (FEMA), Korea Food and Drug Administration (KFDA) and Joint FAO / WHO Expert Committee on Food Additives (JFFA) Has been approved for use as an ingredient and has been used industrially for the purpose of taste and flavor, but there is no report on the physiological activity.

Formula 1

The fillviton of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. As the free acid, inorganic acid and organic acid can be used.

Specifically, the pharmacologically acceptable salts of the fillviton of the present invention include, but are not limited to, hydrochloride, bromate, sulfate, phosphate, citrate, acetate, trifluoroacetate, lactate, tartrate, maleate, fumarate, , Methanesulfonate, glycolate, succinate, 4-toluenesulfonate, gluturonate, ebonate, glutamate, or aspartate, but is not limited to, And salts formed using various inorganic acids and organic acids used. The compounds of the present invention may also exist in the form of solvates (e.g., hydrates).

According to another aspect of the present invention, the present invention provides a method for the treatment and / or prophylaxis of metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome comprising the inventive phytobin or a pharmaceutically acceptable salt thereof as an active ingredient Or a pharmaceutically acceptable salt thereof.

According to the present invention, it has been confirmed that the peptone of the present invention reduces body weight and visceral fat, decreases blood lipid levels, improves blood-liver function index, decreases blood glucose and suppresses metabolic inflammatory response. Accordingly, the compound of the present invention can be effectively used as an effective preventive or therapeutic composition for variously improving various metabolic diseases.

The term " diabetes " as used herein refers to a chronic disease characterized by a relative or absolute lack of insulin resulting in glucose-intolerance. The diabetes of the present invention includes all kinds of diabetes, including, for example, type 1 diabetes, type 2 diabetes and diabetes mellitus. Type 1 diabetes is an insulin-dependent diabetes mellitus, which is mainly caused by the destruction of beta -cells. Type 2 diabetes is non-insulin dependent diabetes, resulting from insufficient insulin secretion after meal or by insulin resistance.

As used herein, the term " dyslipidemia " is a concept including hyperlipidemia. It refers to hypercholesterolemia, hypertriglyceridemia, low HDL-cholesterolemia as well as metabolic abnormalities of lipoprotein, It means an abnormal lipid condition.

As used herein, the term " fatty liver " refers to a state in which fat is accumulated in hepatocytes in excess by liver fat metabolism disorder, which causes various diseases such as angina, myocardial infarction, stroke, arteriosclerosis, fatty liver and pancreatitis .

As used herein, the term " insulin resistance " refers to the fact that cells do not burn glucose effectively because of insulin's ability to lower blood sugar. When insulin resistance is high, the body produces too much insulin, which can lead to hypertension and dyslipidemia as well as heart disease and diabetes. In particular, type 2 diabetes does not notice the increase in insulin in muscle and adipose tissue, and insulin action does not occur.

As used herein, the term " insulin resistance syndrome " is a general term for the diseases caused by insulin resistance, and includes the cell resistance to insulin action, hyperinsulinemia and very low density lipoprotein (VLDL) (Reaven GM, Diabetes, 37) is a concept that is recognized as a risk factor for cardiovascular disease and type 2 diabetes. It is a disease characterized by increased fat, decreased high density lipoprotein (HDL) and hypertension : 1595-607, (1988)). In addition, it is known that insulin resistance increases risk of hypertension, diabetes and smoking as well as promotes atherosclerosis by increasing intracellular oxidative stress and altering signal transduction pathways to induce inflammatory responses (Freeman BA et al, Lab Invest 47 : 412-26, (1982)), Kawamura M et al, J Clin Invest 94: 771-8, (1994)).

As used herein, the term " metabolic disease " is defined as a disease group that is a group of various cardiovascular diseases and risk factors of type 2 diabetes. The term " metabolic disease " It is a concept that covers all aspects. In 1988, Reaven insisted that the common cause of these symptoms was insulin resistance in the body and insulin resistance syndrome. In 1998, the World Health Organization (WHO) explained that insulin resistance explains all the elements of these symptoms The term metabolic syndrome or metabolic disease has been introduced.

According to one embodiment of the present invention, the dyslipidemia which is treated or prevented with the composition of the present invention is hyperlipemia.

As used herein, the term " hyperlipidemia " refers to a disease caused by excessive fat mass in the blood due to insufficient lipid metabolism such as triglycerides and cholesterol. More specifically, hyperlipidemia includes hypercholesterolemia or hypertriglyceridemia with a high incidence of lipid components such as triglyceride, LDL cholesterol, phospholipid and free fatty acid in the blood.

According to one embodiment of the present invention, the fatty liver treated or prevented with the composition of the present invention is a non-alcoholic fatty liver.

The term " non-alcoholic fatty liver (NAFL) " as used herein means a disease in which excessive amounts of fat accumulate in hepatocytes regardless of excessive absorption of alcohol.

According to one embodiment of the invention, the composition of the present invention reduces body weight or diet efficiency. According to another embodiment of the present invention, the composition of the present invention reduces body weight or diet efficiency by 10%, 20% or 30% or more. According to some embodiments of the present invention, the compositions of the present invention may be used to reduce body weight or diet efficiency by 10-60%, 20-60%, 30-60%, 10-50%, 20-50%, 30-50%, 10 -40%, 20-40%, or 30-40%. As evidenced in the following examples, it was confirmed that in the group supplemented with filletone (FD), the high-fat diet decreased the cumulative body weight gain by 33% and the diet efficiency by 32% as compared with the control group (HFD) ).

According to one embodiment of the present invention, the composition of the present invention reduces visceral fat. According to another embodiment of the present invention, the composition of the present invention reduces visceral fat by 10%, 20% or 30% or more. According to a particular embodiment of the present invention, the composition of the present invention comprises 10-60%, 20-60%, 30-60%, 10-50%, 20-50%, 30-50%, 10-40 %, 20-40%, or 30-40%. As shown in the following examples, it was confirmed that the high-fat diet reduced the visceral fat weight by 34% as compared with the control group (HFD) in the group supplemented with fillviton (FD) (Fig. 2a-2b). According to another embodiment of the present invention, visceral fat of the present invention is one or more fats selected from epididymal fat, fat around the kidney, mesentery fat and retroperitoneal fat.

Thus, according to the present invention, it has been confirmed that the composition of the present invention has an effect of preventing, ameliorating or treating obesity by lowering body weight, dietary efficiency and visceral fat significantly compared with the control group.

As used herein, the terms " liver " and " intestine " include cells or tissues, respectively.

According to one embodiment of the present invention, the composition of the present invention reduces plasma lipid concentration. According to another embodiment of the present invention, the plasma lipid of the present invention is a plasma lipid selected from the group consisting of triglyceride, total cholesterol and free fatty acid. According to another embodiment of the present invention, the composition of the present invention reduces plasma lipid concentration by 10%, 20%, 30% or 40% or more. According to a particular embodiment of the present invention, the composition of the present invention comprises 10-60%, 20-60%, 30-60%, 40-60%, 10-50%, 20-50%, 30-50 , 40-50%, 10-40%, 20-40%, 30-40%, 10-30%, or 20-30%. As shown in the following examples, the triglyceride concentration in the supplemented group (FD) supplemented with the flavonone was 33% higher than that of the control group (HFD), 22% total cholesterol and 45% (Fig. 3a-3d).

Therefore, according to the present invention, it has been confirmed that the composition of the present invention has an effect of preventing, ameliorating, or treating dyslipidemia, more specifically, hyperlipidemia, by significantly lowering the plasma lipid concentration than the control group.

According to one embodiment of the present invention, the composition of the present invention reduces liver weight or lipid concentration in liver tissue. According to another embodiment of the present invention, the composition of the present invention reduces liver weight or lipid concentration in liver tissue by 10%, 20%, 30%, 40%, 50% or 60% or more. According to some embodiments of the present invention, the composition of the present invention may be used to reduce liver weight or lipid concentration in liver tissue by 10-80%, 20-80%, 30-80%, 40-80%, 50-80%, 60- 10-70%, 20-70%, 30-70%, 40-70%, 50-70%, 60-70%, 10-60%, 20-60%, 30-60%, 10- 50%, 20-50%, 30-50%, 10-40%, 20-40%, or 30-40%. According to another embodiment of the present invention, the lipid in the liver tissue of the present invention is a lipid selected from the group consisting of triglycerides, cholesterol and free fatty acids. As shown in the following examples, in the group supplemented with filletone (FD), the high fat diet had a liver weight of 35%, a triglyceride concentration of liver tissue of 38%, and a cholesterol concentration of liver tissue in comparison with the control group (HFD) And 31%, respectively, and the free fatty acid concentration of the liver tissue was significantly reduced by 67% (FIGS. 4A-4E).

According to one embodiment of the present invention, the composition of the present invention reduces the activity of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) in the blood. According to another embodiment of the present invention, the composition of the present invention reduces ALT by 10%, 20%, 30%, 40% or 50% or more. According to some embodiments of the present invention, the composition of the present invention comprises 10-70%, 20-70%, 30-70%, 40-70%, 50-70%, 10-60%, 20-60% , 30-60%, 40-60%, or 50-60%. According to another embodiment of the present invention, the composition of the present invention reduces AST by 10%, 20% or 30% or more. According to some embodiments of the present invention, the composition of the present invention comprises 10-60%, 20-60%, 30-60%, 10-50%, 20-50%, 30-50%, 10-40% , 20-40%, or 30-40%. As evidenced in the following examples, it was confirmed that the high fat diet was significantly reduced in the FD supplemented group with 52% of ALT and 34% of AST compared to the control group (HFD) (Figs. 4F and 4G) .

According to the present invention, the composition of the present invention can prevent and / or improve fatty liver, more specifically, nonalcoholic fatty liver by significantly reducing liver weight, lipid concentration in liver tissue, amount of ALT and AST in blood, Or have the effect of treating.

According to one embodiment of the present invention, the composition of the present invention reduces the fasting blood glucose level or the fasting blood insulin concentration. According to another embodiment of the present invention, the composition of the present invention reduces the fasting blood glucose concentration or fasting blood insulin concentration by 10%, 20%, 30%, 40% or 50% or more. According to some embodiments of the present invention, the composition of the present invention may be used to treat fasting blood glucose levels or fasting insulin levels by 10-70%, 20-70%, 30-70%, 40-70%, 50-70%, 10- 60-60%, 20-60%, 30-60%, 40-60%, 50-60%, 10-50%, 20-50%, 30-50%, 10-40%, 20-40% 40%. As evidenced in the following examples, it was confirmed that high-fat diet significantly reduced the fasting blood glucose concentration by 30% and fasting blood glucose by 54% compared with the control group (HFD) in the group supplemented with filletone (FD) 5a-5d).

According to the present invention, the composition of the present invention has an effect of preventing, ameliorating or treating diabetes, and more particularly, type 2 diabetes by significantly lowering the fasting blood glucose level or fasting blood insulin concentration compared to the control group .

According to one embodiment of the present invention, the composition of the present invention reduces inflammatory cytokine concentration in the blood. According to another embodiment of the present invention, the composition of the present invention reduces the inflammatory cytokine concentration in the blood by 10%, 20%, 30%, 40% or 50% or more. According to some embodiments of the present invention, the composition of the present invention may further comprise a concentration of inflammatory cytokines in the blood of 10-70%, 20-70%, 30-70%, 40-70%, 50-70%, 10-60%, 20 30-60%, 30-60%, 10-50%, 20-50%, 30-50%, 10-40%, 20-40%, 30-40%, 10-30% or 20-30% . According to another embodiment of the present invention, the inflammatory cytokine of the present invention is a cytokine selected from the group consisting of IL-6, TNF ?, MCP1 and leptin. As shown in the following examples, in the group supplemented with filletone (FD), high-fat diet was 57% in IL-6, 30% in TNFα, 34% in MCP1 and 22% in leptin (Fig. 6). According to the present invention, it has been confirmed that the composition of the present invention has an effect of preventing, ameliorating, or treating inflammation-induced inflammation induced by obesity by significantly lowering blood inflammatory cytokine concentration in the high-fat diet than in the control group.

According to one embodiment of the present invention, the composition of the present invention may be used for the treatment of visceral fat or liver UCP1 (uncoupling protein 1), UCP3 (uncoupling protein 3), PGC-1α (Peroxisome proliferator-activated receptor- (AMP-activated protein kinase) activation or C / EBPα (CCAAT enhancer-binding proterins), PPARγ (Peroxisome proliferator activated receptor gamma), CD36 (Cluster of Differentiation 36), FAS (LXR), LPL (Lipoprotein Lipase), or ACC (Acetyl-CoA carboxylase) in the rat liver. As evidenced in the following examples, the expression of heat-related genes (ie, UCP1, UCP3 and PGC-1α) in the HFD group was significantly lower than that in the normal group, but FD was decreased by the high-fat diet All of the gene expressions were significantly increased again (FIG. 7A). In addition, the expression of C / EBPα, PPARγ2, CD36, FAS, and leptin, which are involved in adipogenesis, was significantly increased in the HFD group compared to the control group, All of the gene expressions were significantly reduced again (Fig. 7b). In addition, the expression level of β-catenin protein, which is an upper signaling substance that regulates lipogenesis, was significantly increased in the FD group as compared with the HFD group (FIG. 7C). In the HFD group, expression of SREBP, LXRα, LPL, FAS, and ACC, which are important for lipogenesis, were significantly increased compared to that of the normal group, but all of these expressions were significantly decreased again in the FD group ), And the AMPK activation (p-AMPK / AMPK ratio), which is a signal transducing substance promoting fatty acid oxidation, was significantly increased in the FD group (Fig. 8B). Accordingly, the present invention provides a composition for preventing, ameliorating or preventing visceral fat accumulation by reducing the expression of a nuclear transcription factor and its target gene that play a pivotal role in fat production in visceral adipose tissue and increasing the expression of? -Catenin protein The present invention relates to a method for preventing and treating obesity-induced fatty liver disease by reducing the expression of a nuclear transcription factor and its target gene which play a pivotal role in fat synthesis in liver tissues and increasing the activation of signal transducing substances promoting fatty acid oxidation, Improvement or treatment of the disease.

When the composition of the present invention is manufactured from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration or the like. Specifically, the pharmaceutical composition of the present invention can be administered orally.

The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, . The daily dose of the pharmaceutical composition of the present invention is, for example, 0.0001-1000 mg / kg.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

According to still another aspect of the present invention, there is provided a pharmaceutical composition for preventing or ameliorating a metabolic disease selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, To provide a food composition.

According to still another aspect of the present invention, there is provided a method for preventing or ameliorating a metabolic disease selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome which comprises the flavone of the present invention as an active ingredient Lt; / RTI >

Since the functional food or food composition of the present invention shares the above-described pharmaceutical composition with the active ingredient (that is, the flavon), the common content in relation to the pharmaceutical composition is that the composition .

When the composition of the present invention is prepared as a functional food composition or a food composition, it includes not only the flavon of the present invention as an active ingredient, but also a functional food or a component ordinarily added in the production of a food, for example, a protein, a carbohydrate , Fats, nutrients, flavoring agents, and flavoring agents. The above-mentioned carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharides (e.g., maltose, sucrose, etc.); oligosaccharide; Polysaccharides (e.g., dextrin, cyclodextrin and the like); And sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.). Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) may be used as flavorings.

For example, when the functional food composition or the food composition of the present invention is prepared by a drink, it may contain citric acid, An extract, and the like.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a pharmaceutical composition for the prevention or treatment of metabolic diseases comprising phytone as an active ingredient, and a functional food composition for preventing or ameliorating metabolic diseases using the composition.

(b) The peptone of the present invention not only reduces body weight and visceral fat, decreases blood lipid levels, improves blood-liver function indicators, reduces blood sugar levels and suppresses metabolic inflammatory responses, Dyslipidemia, fatty liver, and insulin resistance syndrome. The pharmaceutical composition of the present invention is useful as a pharmaceutical or functional food composition for preventing or treating metabolic diseases selected from the group consisting of dyslipidemia, fatty liver and insulin resistance syndrome.

Figure 1 shows the body weight gain (Figure 1a) and the dietary intake (Figure 1b) of mice fed the experimental diet. Each value is the mean ± standard error (SEM) of 8 mouse measurements. Characters on the graph bar represent significant differences at P <0.001 by one-way ANOVA and Duncan's multiple range test.
Fig. 2 shows photographs of visceral fat tissue (Fig. 2a) and visceral fat weight (Fig. 2b) of the mice consuming the experimental diet. Each value is the mean ± SE of 8 mouse measurements. Characters on the graph bar represent significant differences at P <0.001 by one-way ANOVA and Duncan's multiple range test.
FIG. 3 shows the blood lipid levels (FIG. 3a: mmol / L), FIG. 3b: total cholesterol (mmol / L), FIG. 3c: HDL- : Free fatty acid (μEq / L)]. Each value is the mean ± SE of 8 mouse measurements. Characters in the same column represent significant differences at P < 0.05 by one-way ANOVA and Duncan's multiple range test.
FIG. 4 is a graph showing a non-alcoholic fatty liver-related index (FIG. 4a: liver tissue photograph, FIG. 4b: liver weight (g), FIG. 4c: triglyceride (μmol / g), FIG. 4d: cholesterol / g), Figure 4e: Free fatty acid (占 Eq / g), Figure 4f: Alanine amino group transfer enzyme (IU / L) and Figure 4g: Aspartic acid amino group transfer enzyme (IU / L). Each value is the mean ± SE of 8 mouse measurements. Characters in the same column represent significant differences at P < 0.05 by one-way ANOVA and Duncan's multiple range test.
FIG. 5 is a graph showing the insulin resistance-related index (FIG. 5a: oral glucose tolerance test, FIG. 5b: AUC, FIG. 5c: fasting blood glucose (mmol / L) and FIG. 5d: fasting insulin )]. Characters in the same column represent significant differences at P < 0.05 by one-way ANOVA and Duncan's multiple range test.
FIG. 6 is a graph showing the effect of the experimental diets on inflammatory cytokine (FIG. 6a: IL-6 (pg / ml), FIG. 6b: TNFα (pg / ml), FIG. 6c: MCP1 (pg / ml)]. Each value is the mean ± SE of 8 mouse measurements. Characters in the same column represent significant differences at P < 0.05 by one-way ANOVA and Duncan's multiple range test.
Figure 7 shows changes in gene and protein expression associated with thermogenesis (Figure 7a) and adipogenesis (Figure 7b) of mouse visceral adipose tissue. The top panel is a representative gel photograph of RT-PCR analysis, and the bottom panel shows the relative expression levels of these genes. Data were normalized on the basis of GAPDH mRNA levels, and all expression levels were expressed relative to normal mice in mice. The upper panel of Figure 7c is a representative gel photograph of Western blot analysis and the lower panel shows the relative expression levels of these proteins. Data were normalized on the basis of GAPDH level, and all expression levels were expressed as relative values for normal mice. The results show the results for three independent experiments using an RNA sample pool of eight mice. The letters on the graph bars represent significant differences from other dietary groups at P <0.05 by the one-way ANOVA and the Duncan multiple range test.
FIG. 8 is a graph showing the expression of genes and proteins associated with lipogenesis of mouse liver tissue. FIG. The top panel of FIG. 8A is a representative gel photograph of the RT-PCR analysis and the bottom panel shows the relative expression levels of these genes. Data were normalized on the basis of GAPDH mRNA levels and all expression levels were relative to normal mice. 8B is a representative gel photograph of Western blot analysis of p-AMPK and AMPK, and the bottom panel shows the relative proportion of p-AMPK / AMPK protein expression in liver tissue. Data were normalized based on GAPDH levels and all expression levels were relative to normal mice. The results show the results for three independent experiments using RNA pools of eight mice. The letters on the graph bars represent significant differences from other dietary groups at P <0.05 by the one-way ANOVA and the Duncan multiple range test.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Example 1 Effect of Weight Reduction and Visceral Fat Decrease in Phyvterone in Diabetic Obese Mice

1) Experimental formulas are used for breeding of experimental animals

The obesity induction diet used in the present invention is a high fat diet (HFD: high fat diet, 40% fat calories, 17 g lad + 3% cone oil / 100 g diet) and a filbertone- supplemented high fat diet) had the same composition as HFD, but contained 0.2% of filletone. Metformin or sibutramine (sibutramine), a treatment for obesity, was added to HFD at a level of 0.01% as a reference drug (Table 1). Chow consumed a commercial rodent chow. Philburton, metformin and sibutramine were all purchased from Sigma-Aldrich (USA).

Five week old male C57BL / 6J mice (Orient, Korea) were adapted to a laboratory environment for 1 week with a solid feed, followed by a high fat diet according to the nude method and were randomly placed in the control and experimental groups for a total of 10 weeks. Diets were fed daily with water between 10 am and 11 am, and dietary intakes were measured daily and body weights were measured weekly. In order to prevent sudden change in body weight due to feed intake, the feed pail was removed and the body weight was measured 2 hours later. Blood, liver, and visceral adipose tissue (epididymal fat, kidney peripapillary, mesenteric and retroperitoneal fat) were collected from an experimental animal after fasting for 12 hours or more and anesthetized with diethyl ether. 7.4) and weighed. Blood collected from the abdominal aorta was centrifuged at 1,000 × g for 15 minutes to separate the plasma.

2) Change in weight and visceral fat weight

After 10 weeks of the experiment, the final weight and the 10-week body weight gain were significantly lower in the high-fat diet group compared to the control group (HFD) by 33% in the group supplemented with filletone (FD) (Figs. 1A and 1B). The food efficiency ratio, which was calculated by dividing the cumulative body weight gain during the experimental period by the total dietary intake, was also 32% significantly higher in the FD group than in the HFD group (Figs. 1C and 1D). As a result, it can be seen that the weight-loss efficacy of Philburton is not due to appetite suppression.

After 10 weeks of feeding, the epididymal fat, kidney fat, mesentery fat and retroperitoneal fat were weighed and weighed. The results were as follows: (FD), the weight of epididymal fat, kidney peripherally, mesenteric fat, and retroperitoneal fat was significantly decreased, and the total visceral fat weight of these four areas was significantly reduced by 34% (FIG. 2). Therefore, it has been confirmed that the product has an excellent effect of reducing body weight and visceral fat, which is comparable to that of commercially available obesity treatment (sibutramine) and diabetic agent (metformin).

Example 2: The efficacy and prevention of hyperlipidemia of peptone in diabetic rats

1) Biochemical analysis method of blood

To evaluate the plasma cholesterol, triglyceride and free fatty acid concentrations of the experimental animals raised for 10 weeks, they were repeatedly measured twice using a commercial measurement kit (Bio Clinical System, Korea).

2) Changes in plasma lipid concentration

Plasma lipid concentrations in the experimental group were significantly lower in the FD group compared to the HFD group (33%, 22%, and 45%, respectively). On the other hand, serum HDL-cholesterol concentrations were not significantly different between the experimental groups (FIG. 3). Thus, it can be seen that the flavonone significantly alleviates the hyperlipemia observed in obesity induced by high fat diet, and it is found that the improvement effect of hyperlipemia is similar to or better than the used contrast agent (cybutyramine, metformin) have.

Example 3 Effectiveness of Non-Alcoholic Fatty Liver Prevention and Treatment of Phyllbuton in Dietary Sex Ratio Mice

1) Analysis of lipid concentration in liver tissue

Lipid components of liver tissue were analyzed by Folch et al. (Folch J, Lees M, Sloane Stanley G. A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem . 1957; 226: 497-509). 1 mL of distilled water was added to liver tissue (0.25 g) and homogenized using a Polytron homogenizer (IKA-WERKE GmbH & Co., Ultra-Turrax, Staufen, Germany). 5 mL of a chloroform: methanol solution (2: 1, v / v) was added to the homogenate and mixed thoroughly. The mixture was centrifuged at 1000 xg for 10 minutes to separate the supernatant, and chloroform: methanol 2: 1, v / v) was added, and the same procedure was repeated to completely separate the liver lipid component. 3 mL of a solution of chloroform: methanol: 0.05% CaCl ₂ (3:48:47, v / v / v) was added to the thus-obtained lower layer, which was then mixed for 1 minute and then centrifuged at 1000 × g for 10 minutes. The solution was completely dried with nitrogen gas, and the dried lipid was dissolved in 1 mL of methanol and used for lipid component analysis.

The triglyceride, cholesterol, and free fatty acid concentrations of liver tissue lipid extracts were measured using the same commercial lipid assay kit (Bio Clinical System, Korea) as used for lipid concentration analysis of plasma.

2) Changes in lipid concentrations and liver function levels in liver tissues

The liver weight of the mice fed the experimental diet for 10 weeks showed a significant decrease of 35% in the absolute liver weight (g) compared with the HFD group in the FD group (Figs. 4A and 4B).

The lipid concentrations in the liver tissues were significantly lower in the FD group than in the HFD group (38%, 31%, and 67%, respectively) (Figure 4c-4d). In addition, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, which were measured in plasma, were significantly decreased in FD group compared to HFD group by 52% and 34%, respectively (Figs. 4F and 4G). Therefore, it can be seen that the flavonone has an effect of alleviating the fatty liver phenomenon that occurs in obesity induced by high fat diet, and that the fatty liver improving effect of this flavone is similar to or better than that of the reference drug.

Example 4: Prevention and treatment efficacy of fibrebonne type 2 diabetes and insulin resistance syndrome in diabetic rats

1) Oral glucose tolerance test, fasting glucose and insulin concentration measurement method

Experimental animals were euthanized for 16 hours at the eighth week after oral administration of d-glucose at a dose of 2 g / kg body weight. At 15 minutes, 30 minutes, 60 minutes, and 120 minutes, . The glucose concentration of the collected blood was measured using a strip-operated blood glucose sensor (ONETOUCH Ultra, Inverness Medical Ltd., UK).

On the other hand, the concentration of glucose in fasting plasma collected from mice raised for 10 weeks was measured using a biochemical automatic analyzer (Express Plus, Chiron Diagnostics Co., USA), and the assay kit reagent was purchased from Bio-Clinical System ).

Insulin concentrations on fasting plasma were measured using a mouse insulin ELISA kit (Millipore corporation, USA).

2) Changes in Indicators Related to Type 2 Diabetes and Insulin Resistance Syndrome (Oral Glucose Tolerance)

As a result of oral glucose tolerance test in mice at 8 weeks (2 weeks before dissection), the blood glucose level decreased in the FD group compared to the HFD group and the glucose concentration curve area value (AUC : area under the curve) by 17% (Figs. 5A and 5B). On the other hand, glucose and insulin concentrations of fasting blood collected at the end of experimental breeding were significantly decreased by 30% and 54%, respectively, in the FD group (FIGS. 5c and 5d), compared with the HFD group.

Example 5: Effect of improving the inflammation activation of the flavonone in the dietary-sex-only mouse

1) Analysis of blood inflammatory cytokine concentration

Plasma IL-6, TNFα, MCP1 and leptin concentrations were measured by ELISA using a Milliplex map kit (Millipore corporation, USA).

2) Inflammatory cytokine concentration change in blood

A recent study on the relationship between obesity and the immune system, such as the emergence of the term 'metaflammation' and the interpretation of obesity as 'chronic and low-level inflammation' Is actively underway. For example, TLR4 (toll-like receptor4), which is involved in the innate immune response, is an important factor in the inflammatory response and insulin resistance pathway by using dietary fat (especially saturated fatty acid) as a ligand . When fatty acids (especially saturated fatty acids) are increased in the body fluids by induction of obesity by the high fat diet, when free fatty acids bind to the TLR4 as a substrate, IKK is activated to activate NF-kB and the TNFα And IL-6, which are known to stimulate the inflammation reaction. In addition, TNFα and IL-6 activate SOCS3 (cytokine signaling 3) and JNK, thereby phosphorylating serine residues in IRS (insulin receptor substrate), inhibiting glucose transport, and inducing insulin resistance in peripheral tissues such as liver or muscle .

IL-6 (57% reduction), TNFα (30% reduction), MCP1 (34% reduction) and leptin (22% reduction) were significantly lower in the FD group than in the HFD group (Fig. 6). Therefore, it can be seen that the ingestion of the flavonone significantly improves inflammation activation induced by obesity.

Example 6 Regulation of Gene and Protein Expression Associated with Fat Accumulation and Heat Generation by Fibrin

1) RNA isolation and RT-PCR

The visceral adipose tissue and liver tissue were added to 1 ml of the trizol solution (0.1 g), and the tissue was ground and centrifuged at 12,000 × g for 10 minutes at 4 ° C. The supernatant was transferred to a new tube, and then 200 μl of chloroform was added and stirred. This process was repeated twice, then the supernatant was transferred to a new tube and isopropanol and supernatant were added at a ratio of 1: 1. The mixture was centrifuged at 12,000 × g for 10 minutes at 4 ° C., and the supernatant was removed. To the remaining precipitate was added 1 ml of 70% ethanol, and the suspension was centrifuged at 12,000 × g at 4 ° C. for 10 minutes. And centrifuged for 5 minutes. After removing the ethanol, the tube containing the RNA precipitate was dried at room temperature for 5 minutes, and the RNA pellet was dissolved using nuclease free water. The concentration of RNA samples extracted at 260 nm and 280 nm wavelengths was measured using a UV / VIS spectrophotometer (Beckman coulter, DU730, USA) and agarose gel electrophoresis was performed to confirm the integrity of RNA samples Respectively.

CDNA was synthesized by reverse transcription using oligo dT primer and superscript reverse transcriptase (GIBCO BRL, USA) for RNA samples extracted from visceral adipose tissue and liver tissue. PCR was carried out using the cDNA obtained through reverse transcription as a template and the 5 'and 3' flanking sequences of the gene cDNA to be amplified as primers, and the primer sequences used therein were as shown in Table 2. 1 증폭 of amplified PCR product was electrophoresed on 1% agarose gel to confirm the DNA band.

2) Western Blot analysis

After a certain amount of visceral fat or liver tissue was homogenized with liquid nitrogen and lysis buffer in a mortar, the medium was centrifuged at 13,000 × g at 4 ° C. for 20 minutes and the protein was quantified by the Bradford method. 50 μg of the protein was electrophoresed on SDS polyacrylamide gel and then electroblotted onto PVDF hyperfilm and analyzed for the presence of the antibody, β-catenin, phospho-AMPK (AMP-active protein kinase), AMPK, GAPDH , USA), respectively. The signal of each protein was visualized with a chemiluminescent detection system (Amersham, UK) and the band thickness was quantified using Quantity One analysis software (Bio-Rad Laboratories, USA).

3) Changes in gene and protein expression of visceral adipose tissue

Expression of heat-related genes (UCP1, UCP3) and transcription factor (PGC-1α) in visceral adipose tissue by RT-PCR was found to be higher in the HFD group than in the normal group Were significantly decreased. The supplementation of fillviton significantly increased UCP1, UCP3, and PGC-1α gene expression, which were decreased by high-fat diet intake (Fig. 7a).

In the HFD group, the expression of C / EBPα and PPARγ2, which are important for adipogenesis, and the expression of CD36, FAS and leptin, which are the target genes of these transcription factors, Respectively. As a result of supplementing the mice fed high fat diet with filletone, nuclear transcription factor and its target gene expression, which were increased by ingestion of high fat diet in visceral adipose tissue, again decreased significantly (Fig. 7b). The amount of β-catenin protein expression, which is an upper signaling substance that regulates lipogenesis by Western blotting, was evaluated in visceral adipose tissues, which was significantly increased in the FD group than in the HFD group (FIG. 7C). Therefore, supplementation with fillverone prevented the accumulation of visceral fat by decreasing the nuclear transcription factor and its target gene expression, which play a pivotal role in lipogenesis in visceral adipose tissue, and by increasing β-catenin protein expression.

4) Changes in gene and protein expression in liver tissue

As a result of RT-PCR, the expression levels of mRNA in liver tissues were compared with those of the HFD group. The nuclear transcription factors SREBP and LXRα, which play an important role in lipogenesis, Both LPL, FAS and ACC genes were significantly increased. On the other hand, as a result of supplementation with filletone, the nuclear transcription factor and its target gene expression, which were increased in the liver tissue by ingestion of the high-fat diet, were all decreased again (FIG. AMPK activation (p-AMPK / AMPK ratio), which is a signaling substance promoting fatty acid oxidation using western blot, was evaluated in liver tissue, which was significantly increased in the FD group compared to the HFD group (Fig. 8B). Thus, supplementation with fillverone improves obesity-induced fatty liver disease by reducing the nuclear transcription factor and its target gene expression, which play a central role in lipogenesis in liver tissue, and by increasing the activation of signaling substances that promote fatty acid oxidation It can be seen that there is an effect.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims

A medicament for the prophylaxis or treatment of metabolic disease selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome which comprise filbertone as an active ingredient. Gt;

The composition of claim 1, wherein the dyslipidemia is hyperlipidemia.

The composition of claim 1, wherein the fatty liver is a non-alcoholic fatty liver.

2. The composition of claim 1, wherein the composition reduces body weight or diet efficiency.

2. The composition of claim 1, wherein the composition reduces visceral fat.

2. The composition of claim 1, wherein the composition reduces plasma lipid concentration.

2. The composition of claim 1, wherein the composition reduces liver weight or lipid concentration in liver tissue.

The composition of claim 1, wherein the composition reduces the activity of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in the blood.

2. The composition of claim 1, wherein the composition reduces fasting blood glucose concentration or fasting blood insulin concentration.

2. The composition of claim 1, wherein the composition reduces serum inflammatory cytokine levels.

The composition according to claim 1, wherein the composition is selected from the group consisting of visceral fat or liver UCP1 (uncoupling protein 1), UCP3 (uncoupling protein 3), PGC-1α (Peroxisome proliferator- (AMP-activated protein kinase) activation, or C / EBPα (CCAAT enhancer-binding proterins), PPARγ (Peroxisome proliferator activated receptor gamma), CD36 (Cluster of Differentiation 36), FAS , Sterop regulatory element binding factor 1c (SREBP1C), Liver X receptor alpha (LXRα), Lip (Lipoprotein Lipase) or ACC (Acetyl-CoA carboxylase).

A functional food composition for the prevention or amelioration of a metabolic disease selected from the group consisting of obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome, which comprises filletone as an active ingredient.